Allstocks.com's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

» Allstocks.com's Bulletin Board » .11 and Up! » OXIS - Sperm News » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    
Message:

HTML is enabled.
UBB Code™ is enabled.

 

Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?
Options


Disable Graemlins in this post.


 


T O P I C     R E V I E W
Persia  - posted
MONTVALE, N.J., May 09, 2007 (BUSINESS WIRE) --
Oxis International Inc. (OTCBB: OXIS) announced today that its lead antioxidant compound L-ergothioneine (ERGO) showed dramatic results in preserving function of sperm cells undergoing freezing and thawing. These experiments were designed by an expert in equine fertility, Lisa Metcalf, MS DVM Diplomate, American College of Theriogenology and executed in independent animal fertility laboratories. ERGO increased sperm cell viability by 15-20% in pre-clinical and clinical studies as measured by total and progressive motility, when added to known cell extender preservatives in general use in the fertility field. Percentage increases of this magnitude are significant considering the large numbers of cells involved.

These results dramatically indicate new potential applications for ERGO in various fields in which cell preservation is crucial, including, but not limited to, applications involving stem cells, sperm cells, oocytes (ova), chondrocytes (cartilage), and cell cloning Oxis has filed protective patents to cover these potential new applications for ERGO.

"I am extremely encouraged by these promising preliminary results suggesting that ERGO has significant potential to enhance fertility. The broad applications for this compound suggest that additional testing should be commenced immediately to determine whether these results can be replicated," said Dr. Metcalf, who currently serves as the Oregon Veterinary Racing Commissioner. She is also the immediate Past-President of the Northwest Equine Practitioners Association and on the Chairs Council of the Oregon Humane Society and is an internationally recognized speaker and author.

The basic concept underlying this experiment is that all mammalian cells, whether embryonic or adult, undergo oxidative stress when removed from the host body or organ. The host under normal conditions, to maintain cell integrity and viability, neutralizes oxidative damage through cellular antioxidants. When the balance shifts to a level that cannot be neutralized, apoptosis, or programmed cell death occurs. Freezing and thawing of collected sperm cells represents an excellent oxidative stress model to test the ERGO antioxidant hypothesis.

ERGO is a unique, naturally occurring antioxidant that is abundant in most plants and animals. ERGO cannot be synthesized by humans and therefore is available only from dietary sources. OXIS was the first company to develop a patented, synthetic process for the manufacture of pure ERGO. The Oxis proprietary manufacturing process has been approved in North America, Japan and Western Europe. A significant role for ERGO in cellular function is also shown by the recent discovery in humans of a transport system specific only for ERGO ("Discovery of the Ergothioneine Transporter"; D. Grundemann et al; Proceedings of the National Academy of Sciences, USA, 2005 April 5; 102 (14): 5256-5261)

"The ability to harvest, propagate, and maintain human cells/cell lines, whether from an embryo or adult donor, underlies the basis of any successful cell preservation system and the broad therapeutic applications," stated Marvin S. Hausman M.D., President and CEO, of OXIS. "These results suggest that ERGO has the potential to prolong cellular life through its potent antioxidant activity and may represent enabling technology, especially for the stem cell industry. OXIS intends to offer licenses to this technology to assist any company involved in cell harvest and preservation."

The ability of ERGO to potentially prolong cell life and cell function has applications beyond cell preservation. OXIS is currently developing and evaluating diagnostic proprietary biomarkers of oxidative stress which can be specifically connected to antioxidant nutritional supplementation with application to athletic performance as well as patients with specific diseases.

Dr. Metcalf received her DVM degree from The Virginia-Maryland Regional College of Veterinary Medicine and her MS in Endocrinology from UC Davis. She is a member of the Phi Zeta Veterinary Honor Society and received the Robert M. Hogsett Memorial Award for clinical proficiency, professionalism, and leadership. Dr Metcalf is board-certified in theriogenology, the specialty practice of animal reproduction.
 



Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share